Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592033 | SCV000709046 | uncertain significance | not provided | 2017-06-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002531106 | SCV002931283 | uncertain significance | Combined oxidative phosphorylation defect type 7; Spastic paraplegia | 2022-05-06 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 502352). This variant has not been reported in the literature in individuals affected with C12orf65-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 18 of the C12orf65 protein (p.Pro18Leu). |